Procedures & recovery · patient guide

Radiotherapy plan review in China explained

A radiotherapy plan review asks a radiation oncologist to examine whether the proposed target volumes, organ-at-risk constraints, dose schedule and image guidance fit the patient's diagnosis and records. In China, as anywhere, the treating team holds responsibility for the final plan. A review can raise questions and alternatives, but it cannot confirm suitability, book treatment or guarantee an outcome.

Go to the practical guidance ↓
AI illustration: A doctor in a white coat consulting with a female patient at a table in a clinical setting.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What a radiotherapy plan review actually examines

External beam radiotherapy is delivered by directing ionising radiation at a defined volume while limiting dose to nearby healthy tissue. The plan is the technical expression of a clinical decision: what to treat, what to spare, how much dose, in how many fractions, and how the patient's position will be verified each day. A plan review looks at that whole chain rather than only the dose distribution picture.

A radiation oncologist reviewing a plan would normally want to understand the diagnosis and stage, the intent of treatment (curative, adjuvant or palliative), whether radiotherapy is being combined with surgery or systemic therapy, and what the previous imaging shows. They then consider whether the target volumes match the known disease, whether organ-at-risk constraints are reasonable for that site, and whether the fractionation and technique are consistent with the stated aim.

This is a clinical judgement, not a checklist pass. Two experienced clinicians can reasonably differ on contouring margins or acceptable constraints. A review is most useful when it produces specific questions: why this margin, why this technique, what would change if a constraint cannot be met, and what the alternatives are. Those questions belong with the treating team, who know the patient's full situation and carry responsibility for delivery.

It also helps to be clear about what a review is not. It is not a new diagnosis, not a guarantee that the plan is correct or incorrect, and not a substitute for the treating hospital's own quality assurance, physics checks and on-treatment verification. If a review raises a concern, the next step is a conversation between clinicians, not a unilateral decision by the patient based on one opinion.

Radiotherapy in China

The records a radiation oncologist needs to look at a plan

A plan cannot be assessed from a summary alone. The reviewer needs the material the original team used, plus the plan output itself. What is available varies by hospital and by how far treatment has progressed, so it is reasonable to ask the treating hospital what it can release and in what format.

Imaging is central. That normally means the diagnostic scans on which the plan was based, ideally in DICOM format rather than photographs or compressed images, because DICOM preserves the geometry and allows the reviewer to see the actual slices. If the plan was built on a planning CT, that dataset matters too. A written radiology report alone does not let a reviewer judge target coverage or organ dose.

The plan documents matter equally. These may include the dose distribution, dose-volume histogram data, the structure set showing how targets and organs at risk were outlined, and a record of the prescribed dose and fractionation. The pathology report, operative notes if there was surgery, and a list of current medicines and relevant blood results help the reviewer understand the clinical context. Prior radiotherapy records are important if the area has been treated before.

Language and format are practical hurdles. Reports in another language may need translation, and the reviewer may need to confirm which documents are legible and complete. It is better to send a smaller set of genuinely useful files than a large archive with the key plan data missing. If something is unavailable, say so rather than substituting a summary, because the reviewer needs to know the limits of what they are assessing.

Questions to ask before accepting a plan in China

The most useful preparation is a short list of questions written before the appointment. These are questions for the treating radiation oncologist, and the answers should be recorded so they can be discussed with family or a referring doctor. The aim is to understand the reasoning, not to test the clinician.

Ask what the treatment is intended to achieve and how the plan supports that aim. Ask which structures were outlined as targets and which organs at risk were constrained, and whether any constraint is close to its limit. Ask what technique is proposed and why it was chosen over alternatives available at that hospital. Ask how the patient's position will be verified during treatment and what happens if the plan needs adjustment.

It is also reasonable to ask about the expected side effects for this specific plan and site, and what the team will monitor. These are general clinical discussions the treating team is best placed to have. A reviewer at a distance can comment on the documents, but cannot examine the patient or observe the response to treatment.

Finally, ask what would make the team change the plan. Answers to that question often reveal more about the clinical reasoning than a description of the plan itself. If the patient is considering a review elsewhere, tell the treating team, because transparency makes it easier to obtain records and to reconcile any differences in opinion.

How a records-based review fits alongside treatment in China

Some international patients want an independent look at a plan before starting, or while deciding between options. A records-based review can be arranged while the patient remains at home, and it is optional rather than a prerequisite for treatment. It produces an opinion on the documents supplied, which the patient can then discuss with the treating hospital.

The limits are important. A reviewer who has not examined the patient, seen the imaging in full context or spoken with the treating team is working from a partial picture. Their comments may confirm that the plan looks reasonable, may raise questions, or may identify that key information is missing. None of these outcomes establishes that the patient is suitable for a particular treatment, that a hospital will accept them, or that a different plan would produce a better result.

If a review raises a substantive concern, the appropriate route is usually for the two clinical teams to communicate, with the patient's consent, so that the technical points can be resolved. Patients should be cautious about acting on a single remote opinion without giving the treating team a chance to respond. Radiotherapy decisions carry real trade-offs between tumour control and normal-tissue effects, and those trade-offs depend on details a remote reviewer may not have.

ChinaSpecialistCare can help identify missing records and suggest a relevant next step, but the clinical assessment, the plan and the decision to treat belong to the hospital and its licensed clinicians. A review is information for a conversation, not a verdict.

Safety, quality assurance and what the hospital must confirm

Questions about safety are reasonable, and they are best directed at the treating hospital. Radiotherapy departments operate quality-assurance processes covering machine calibration, treatment planning checks, patient positioning and on-treatment imaging. How these processes are organised, documented and communicated to patients varies between hospitals, so ask the specific hospital what its process involves rather than assuming a standard.

For an international patient, practical questions matter too: whether the department can provide information in English, how consent discussions are conducted, what the patient is told about side effects and when to report them, and how follow-up after treatment is arranged. These are administrative and communication questions the hospital can answer directly. They do not replace the clinical discussion, but they affect how well a patient can participate in decisions.

It is also fair to ask how the plan will be reviewed during treatment. Radiotherapy is not always a single fixed event; position verification, imaging and clinical review during the course allow the team to check that delivery matches the plan. What that involves for a particular technique and site is a question for the treating team.

No article can confirm that a particular hospital's process is adequate for an individual. The hospital decides suitability, and the treating clinicians decide the plan. A patient's job is to ask clear questions, understand the answers and raise concerns early.

A practical next step for an international patient

Start by gathering the diagnosis, the imaging in DICOM format if available, the plan documents and a short note of the main question. A brief summary is enough for a first enquiry; there is no need to send a complete medical archive or payment details at the outset. The team can then explain what is missing and what a review could reasonably cover.

An initial enquiry is free and does not commit the patient to buying a proxy consultation or any other service. If a records-based opinion is wanted, its scope can be agreed first. The treating hospital remains responsible for assessing suitability, producing the plan and deciding on treatment, and any review should be discussed with that team before decisions are made.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Radiotherapy in China
  2. payment

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.